T 2163/22 (Apixaban IV/Bristol-Myers) of 01.02.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T216322.20240201
- Date of decision
- 1 February 2024
- Case number
- T 2163/22
- Petition for review of
- -
- Application number
- 17178613.0
- IPC class
- A61P 7/02A61K 9/20A61K 31/4545
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- APIXABAN FORMULATIONS
- Applicant name
- Bristol-Myers Squibb Holdings Ireland
Unlimited Company
Pfizer Inc. - Opponent name
- ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Kutzenberger Wolff & Partner
Zentiva k.s.
Medichem S.A.
Teva Pharmaceutical Industries Ltd
Sandoz AG
Generics (U.K.) Limited
STADA Arzneimittel AG - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 112(1)European Patent Convention Art 54European Patent Convention Art 56
- Keywords
- Novelty - (no)
Inventive step - (no)
Inventive step - comparative example suitable starting point for assing inventive step
Referral to the Enlarged Board of Appeal - (no) - Catchword
- -
- Cited cases
- T 0205/83T 0056/87T 0297/91T 0776/96T 0177/98T 0414/98T 0564/02T 0501/04T 1711/16T 0032/17
- Citing cases
- T 1179/23
Order
For these reasons it is decided that:
1. The appeal is dismissed.
2. The request for referral to the Enlarged Board of Appeal is refused.